MedPath

Evaluation of Human Milk Fortifiers in Preterm Infants

Not Applicable
Completed
Conditions
Infant Growth
Interventions
Other: Human Milk Fortifier B
Other: Human Milk Fortifier A
Registration Number
NCT02307760
Lead Sponsor
Abbott Nutrition
Brief Summary

The purpose of this study is to assess growth of preterm infants fed human milk supplemented with one of two commercially available human milk fortifiers.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
164
Inclusion Criteria
  • Birth weight of 700 g-1500 g.
  • ≤ 32 weeks and 0 days GA at birth.
  • Appropriate for GA (AGA).
  • Enteral feeding of human milk initiated by 21 days of life (birth date is day of life 0).
  • Mother agrees to provide human milk as the exclusive feeding during the study period; use of donor milk is permitted if the plan is that it will be fortified.
  • Parent(s) agrees to allow infant to receive both human milk and HMF.
  • Singleton or twin births only.
Exclusion Criteria
  • Enteral feeding of preterm infant formula or HMF for > 7 days.
  • Expected to be transferred to another facility and will not be able to be followed for at least 15 days.
  • Serious congenital abnormalities or underlying disease that may affect growth and development.
  • 5 minute APGAR ≤ 4.
  • Steroids used at the time of randomization.
  • Grade III or IV periventricular/intraventricular hemorrhage (PVH/IVH).
  • Mechanical ventilator dependence.
  • Maternal incapacity: including maternal cocaine or alcohol abuse during pregnancy or current, or if the mother or infant is currently receiving treatment consistent with HIV therapy.
  • Infant has a history of major surgery (intra-thoracic or intra-abdominal procedures or other surgery requiring general anesthesia).
  • Asphyxia defined as progressive hypoxemia and hypercapnia with significant metabolic acidemia characterized by APGAR score <3 at 10 minutes, seizures within the first 12 hours of life, or a cord blood gas < 7.0 and seizures and/or severe tonic abnormalities in the first 12 hours of life (24).
  • Confirmed necrotizing enterocolitis (Bell's Stage II or III, Appendix J) or confirmed sepsis (positive culture requiring antibiotic treatment).
  • Infant has any other condition that, in the opinion of the investigator, precludes participation in the study.
  • Participation in another study that has not been approved as a concomitant study by AN.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Study Human Milk Fortifier BHuman Milk Fortifier BNon-acidified processing method.
Study Human Milk Fortifier AHuman Milk Fortifier AAcidified processing method.
Primary Outcome Measures
NameTimeMethod
Weight GainStudy Day 1 to Study Day 29 (or discharge, whichever happens first)

scale measurement g/kg/d

Secondary Outcome Measures
NameTimeMethod
Gastrointestinal ToleranceStudy Day 1 to Study Day 29 (or discharge, whichever happens first)

healthcare professional completed questionnaire

LengthStudy Day 1 to Study Day 29 (or discharge, whichever happens first)

measured cm/wk

Head CircumferenceStudy Day 1 to Study Day 29 (or discharge, whichever happens first)

measured cm/wk

Trial Locations

Locations (18)

University of South Alabama Children's and Women's Hospital

🇺🇸

Mobile, Alabama, United States

Memorial Hospital of South Bend

🇺🇸

South Bend, Indiana, United States

MetroHealth Medical Center

🇺🇸

Cleveland, Ohio, United States

All Children's Hospital / Johns Hopkins

🇺🇸

Saint Petersburg, Florida, United States

South Miami Hospital

🇺🇸

Miami, Florida, United States

Cohen Children's Medical Center of NY at North Shore

🇺🇸

Manhasset, New York, United States

Cohen Children's Medical Center of NY

🇺🇸

New Hyde Park, New York, United States

Cook Children's Medical Center

🇺🇸

Fort Worth, Texas, United States

Lehigh Valley Health Network

🇺🇸

Allentown, Pennsylvania, United States

Doctors Hospital at Renaissance/Women's Hospital at Renaissance

🇺🇸

Edinburg, Texas, United States

Texas Health and Education Institute

🇺🇸

Fort Worth, Texas, United States

North Central Baptist Hospital

🇺🇸

San Antonio, Texas, United States

University of Louisville

🇺🇸

Louisville, Kentucky, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

Medstar Georgetown University Hospital

🇺🇸

Washington, D.C., District of Columbia, United States

Yale University

🇺🇸

New Haven, Connecticut, United States

Wheaton Franciscan Heathcare Inc.- St. Joseph

🇺🇸

Milwaukee, Wisconsin, United States

Banner - University Medical Center Phoenix

🇺🇸

Phoenix, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath